MedTrace Logo

Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes

NCT00998699 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2014-03-04

No results posted yet for this study

Summary

The study hypothesis is that XOMA 052 may inhibit beta-cell destruction and enhance beta-cell regeneration.

The purpose of this study is to assess the effects of XOMA 052 on beta-cell function and insulin production.

Conditions

Interventions

DRUG

Xoma 052

Sterile solution subcutaneously administered every 4 weeks for 12 weeks

DRUG

Placebo

Sterile solution subcutaneously administered every 4 weeks for 12 weeks

Sponsors & Collaborators

  • Juvenile Diabetes Research Foundation

    collaborator OTHER

  • XOMA (US) LLC

    lead INDUSTRY

Principal Investigators

  • Marc Donath, MD · UniversitaetsSpital Zuerich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00998699 on ClinicalTrials.gov